Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa

Nmazuo W. Ozuah,1-3,* Joseph Lubega,1,2,4,* Carl E. Allen,1,2 and Nader Kim El-Mallawany1,2

1Section of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX; 2Texas Children’s Cancer and Hematology Centers, Houston, TX; 3Global HOPE Malawi, Lilongwe, Malawi; and 4Global HOPE Uganda, Kampala, Uganda

Long-term cure of childhood Burkitt lymphoma (BL) in sub-Saharan Africa after treatment with single-agent cyclophosphamide has been documented for more than half of a century. Contemporary cure rates for the highest-risk patients with BL in high-income countries exceed 90% using intensive multiagent chemotherapy. By contrast, the majority of African children with BL still die. Data spanning 5 decades in Africa have repeatedly shown that the children most likely to achieve cure with limited cyclophosphamide regimens are those with lower-stage disease isolated to the jaw. Attempts to intensify the cyclophosphamide monotherapy backbone with the addition of vincristine, low-dose methotrexate, prednisone, doxorubicin, and/or low-dose cytarabine have not yielded significant improvement. High-dose methotrexate is a critical component in the treatment of childhood BL worldwide. Although initial efforts in Africa to incorporate high-dose methotrexate resulted in high treatment-related mortality, more recent collaborative experiences from North and West Africa, as well as Central America, demonstrate that it can be administered safely and effectively, despite limitations in supportive care resources. Recognizing the unacceptable disparity in curative outcomes for BL between the United States/Europe and equatorial Africa, there is a critical need to safely adapt contemporary treatment regimens to optimize curative outcomes amid the resource limitations in regions where BL is endemic. Here, we critically review reports of BL treatment outcomes from low- and middle-income countries, in addition to data from high-income countries that predated modern intensified regimens, to identify potential strategies to improve the therapeutic approach for children suffering from BL in sub-Saharan Africa.

Introduction

The history of Burkitt lymphoma (BL) offers a snapshot into the pervasive survival disparity for childhood cancer between high-income countries (HICs) and the rest of the world.1 After its description by Denis Burkitt and colleagues in Uganda in the 1960s, BL became recognized as the most common non-Hodgkin lymphoma (NHL) of childhood worldwide.2,3 Considered the most common overall pediatric cancer in regions of sub-Saharan Africa (SSA) where malaria is endemic, “endemic” BL has captivated clinicians and scientists alike for more than half a century. Tumor biopsies from African children with BL have revealed fundamental mechanisms of cancer biology, from the original discovery of Epstein-Barr virus and the c-myc oncogene, to determination of the genomic signature of BL.4-8 Parallel to the biological discoveries related to BL, pediatric cancer cooperative group trials in HICs have steadily improved the outcomes of children with BL by generating evidence for improving diagnostic accuracy, staging classification, risk stratification, supportive care, and risk-adapted chemoimmunotherapy. The
impact of progressive cooperative group trials is highlighted, in part, by contemporary pediatric BL cure rates that exceed 90% in HICs.\textsuperscript{25,26} However, advances in HICs are not directly applicable to the African health care landscape, and, putatively, to the biology of endemic BL. Therefore, the majority of children with BL worldwide have not benefited from these advances. Best estimates of long-term survival of pediatric BL in SSA today are 30% to 50%, which are unchanged from the 1970s era, the discovery of BL and the dawn of the field of pediatric oncology. To identify strategies to accelerate cure rates for children with endemic BL, we critically review the evolution of pediatric BL treatments and outcomes from trials and retrospective clinical reports in SSA, in parallel with developments in HICs.

**Context of BL treatment and outcome studies in SSA**

Interpretation of reports describing clinical outcomes of BL in SSA must take into account the heterogeneity of diagnostic and staging tools, timing and dosing of the intended chemotherapy drugs, response criteria, and duration of follow-up. These factors are dictated by available infrastructure for care and clinical research and the paucity of established cooperative groups to enable multicenter trials. Significant variability might exist between treating centers, for different children within a given treatment center, and for the same patient during a treatment course. For example, many centers in SSA diagnose BL based on clinical presentation only or tumor morphology alone.\textsuperscript{17} These modalities have been shown to have limited diagnostic accuracy.\textsuperscript{18,19} Moreover, staging of patients with BL requires routine microscopy of cerebrospinal fluid (CSF) samples and bone marrow evaluation to define extent of disease; however, most centers in SSA lack resources to consistently perform these staging tests. Similarly, assessment of treatment response relying solely on symptoms and clinical examination may miss subtle tumors, and it has not been standardized across centers or between clinicians. Lastly, the majority of data are limited to retrospective review of records, which is impacted by access to records, accuracy of clinical information, and potential underrepresentation of dead and lost patients.\textsuperscript{20} Acknowledging these limitations, review of studies from SSA is valuable to demonstrate prevailing practices, as well as trends and gaps in patient outcomes, which can inform application of evidence from HICs.

The quality and speed of diagnostic and staging processes have critical implications in long-term outcomes for patients. Diagnostic delays can consequently lead to patients having a greater burden of disease and more complex clinical scenarios (eg, higher risk for tumor lysis syndrome or more severe neurologic complications from spinal cord compression/cranial nerve palsies). Widespread societal poverty has detrimental impact on access to care, often leading to delays in diagnosis; the financial resources required for long-distance transportation to tertiary care medical facilities can be prohibitive and a major hurdle to overcome. Additionally, diagnostic delays within the medical system are important to consider. Patients often present to medical care initially at smaller rural health care centers where, aside from the dramatic and conspicuous presentation of a jaw tumor, there is lack of awareness or recognition of other clinical characteristics of BL, such as an abdominal mass. This, coupled with the challenge of accessing referral networks to the limited number of quaternary-level medical facilities that provide diagnostic and therapeutic resources for childhood cancer, lead to further delays in diagnosis. In efforts to overcome these limitations, international collaborations have focused efforts to bolster diagnostic accuracy and efficiency through telepathology portals.\textsuperscript{21-23} These types of global partnerships have the potential to improve accuracy of diagnosis and treatment through knowledge transfer between institutions in SSA and HICs. Enhancing the local capacity of the health care workforce and creating programs to train pediatric hematology/oncology experts are also essential to deliver the complex care required to support the intense therapy that is necessary to cure BL.\textsuperscript{24}

**Historical use of cyclophosphamide monotherapy for endemic BL**

Treatment of BL at the Uganda Cancer Institute in the 1960s and 1970s represented some of the earliest experiences with chemotherapy in cancer treatment worldwide.\textsuperscript{25} Denis Burkitt and his contemporaries showed that even a single dose of cyclophosphamide monotherapy could induce clinical remission in 70% to 80% of patients with BL.\textsuperscript{26,27} However, only ~25% of these patients had sustained remission, even after multiple doses of cyclophosphamide were administered.\textsuperscript{26} It became apparent that patients with advanced-stage disease suffered significantly higher rates of relapse and death.\textsuperscript{25,26,28} Current understanding of the pharmacodynamics of anticancer chemotherapy recognizes that cancer cells almost inevitably develop resistance to cytotoxic agents through multifaceted mechanisms. Specific to cyclophosphamide, resistance may involve decreased activation by liver cytochromes, decreased entry into or increased exit from tumor cells, increased deactivation inside tumor cells, increased cellular thiol level, increased activity of glutathione S-transferases, increased aldehyde dehydrogenase (ALDH1A and ALDH3) activity, and increased DNA repair capacity.\textsuperscript{29,30} Combination chemotherapy is a key strategy to overcome tumor resistance to cytotoxic agents.\textsuperscript{31} In addition to the cytotoxic effect of cyclophosphamide, it has an immunomodulatory effect that may play a role in effectiveness against lymphoid malignancies.\textsuperscript{32}

**Historical cyclophosphamide-based combination therapy for endemic BL**

The incorporation of multiple low-intensity chemotherapeutic agents into the backbone of cyclophosphamide did not significantly improve long-term overall survival (OS) for endemic BL in the early years of the experience.\textsuperscript{25,27} Such regimens included cyclophosphamide, vincristine, methotrexate (MTX), and cytarabine, as well as cyclophosphamide, vincristine, and MTX (COM), both of which used low-dose MTX (ie, cumulative doses per cycle < 100 mg/m$^2$).\textsuperscript{25} Notably, these combinations were administered uniformly through the course of treatment, regardless of the risk of tumor lysis syndrome and with no induction and consolidation cycle variations. Although well tolerated, these low-intensity combinations were not superior to cyclophosphamide monotherapy.\textsuperscript{27} It was also still apparent that, like cyclophosphamide monotherapy, advanced-stage disease was associated with high rates of early relapse after treatment with these low-intensity regimens, including in the central nervous system (CNS).\textsuperscript{25,27} Early strategies to treat and prevent CNS relapse in SSA included the use of systemic agents purported to cross the blood-brain barrier, intrathecal administration of cytotoxic agents, and cranial
radiotherapy. The addition of CNS-directed systemic chemotherapy in the form of lomustine delayed CNS relapses but was associated with increased mortality. Similarly, short-term intrathecal chemotherapy showed no efficacy in preventing CNS relapses. Borrowing from the experience of using cranial irradiation to prevent CNS relapse in children with acute lymphoblastic leukemia in HICs, Olweny et al conducted a trial of craniospinal irradiation vs no additional CNS-directed therapy in 22 children with BL following a CNS remission after cyclophosphamide monotherapy or COM. In this small cohort, more CNS relapses (54%) were observed in the irradiated group compared with the no-irradiation group (36%); ultimately, relapse frequency was found to correlate with advanced-stage disease. Subsequent studies from around the world showed severe long-term adverse effects of cranial irradiation in children; hence, attempts to use this modality in BL were abandoned.

Contemporary standards and efforts to improve BL treatment in SSA

Current standards of BL treatment in SSA are still primarily based on the successes of pioneering trials from the 1970s with cyclophosphamide as the backbone agent, without differentiation of staging or risk group. Survival rates have plateaued over the past 40 years, and efforts to improve have stalled since then. Contemporary efforts to improve outcomes within the cyclophosphamide-based paradigm have included the addition of various low doses of MTX, vincristine, doxorubicin, and prednisone. The collective experience has demonstrated cohort survival rates ranging from 30% to 50%, with mortality primarily attributed to tumor progression or recurrence (Table 1). Patients with stage III/IV BL have achieved survival of 40% to 60%, whereas survival for stage III/IV BL (typically involving the abdominal cavity, bone marrow, or CNS) has remained <30%. This is particularly relevant because numerous studies in SSA have demonstrated that abdominal mass has become at least as common as jaw mass as a presenting feature of endemic BL (Figure 1).

A recent clinical quality improvement project at the Uganda Cancer Institute is emblematic of the lack of progress in improving outcomes: over a 5-year period (2012-2017), 180 children with pathology-confirmed diagnoses of BL were treated with COM, with resources dedicated to ensuring accurate diagnosis, chemotherapy availability, and treatment compliance. Despite mitigating limitations of access to care, the 4-year OS was 44%, similar to results from clinical trials at the same center from the 1970s. Although the International Network for Cancer Treatment and Research had earlier reported event-free survival (EFS) and OS of 54% and 67%, respectively, at 1 year using a similar regimen with a slightly higher dose of MTX (75 mg/m² compared with doses of 15-45 mg/m² used in other COM trials), that study built in a salvage regimen of ifosfamide, etoposide, and cytarabine for patients who failed COM. Thus, the survival rates are not reflective of the treatment response to COM alone. Follow-up time for survivors was not reported for the cohort, creating uncertainty about whether the reported outcomes represented short-term response vs long-term remission. These survival rates have not been reproduced elsewhere in the region using similar regimens.

Another contemporary therapeutic strategy to improve on the suboptimal results of historic cyclophosphamide-based regimens has been based on the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) adult mature B-cell NHL regimen. A study from Blantyre, Malawi reported a 1-year disease-free survival of 66% for patients with stage III/IV BL utilizing a regimen that added 2 doses of doxorubicin to a standard backbone of cyclophosphamide, vincristine, and prednisone. However, a similar regimen implemented in Nairobi, Kenya reported a 1-year EFS of 31%, whereas CHOP-like regimens used in Lilongwe, Malawi were not due to treatment-related mortality (TRM), which were very similar (8%-16%). It is challenging to definitively explain the differences in treatment outcomes, but potential factors may include differences in inclusion criteria, methods of risk stratification, response measurement, or follow-up. Additionally, the cohort in Blantyre may have benefited from expedited pathology analyses through the aforementioned telepathology collaboration via a partnership with a United Kingdom–based institution, potentially enabling a patient population with less-advanced-stage disease. Ultimately though, the less favorable outcomes from the region are similar to historic results from St. Jude Children’s Research Hospital (Memphis, TN) from the 1970s, where a similar regimen combining cyclophosphamide, vincristine, prednisone, and doxorubicin, with or without involved-field radiation therapy, resulted in a 2-year disease-free survival of 38.8% for patients with stage III/IV disease.

In summary, despite the promising glimpse of responses and occasional cure for children with endemic BL receiving treatment in SSA in the 1970s, progress has stalled over the past 50 years, with low-intensity cyclophosphamide-based chemotherapy as a persistent therapeutic strategy. Although studies are largely retrospective with variable data integrity, at best, this chemotherapy approach affords long-term survival to approximately a third of children.

Role of high-dose MTX in pediatric BL regimens in HICs

In the 1970s and 1980s, chemotherapy regimens and treatment outcomes for children in SSA were similar to their counterparts in the United States. For example, 2-year EFS at St. Jude Children’s Research Hospital was 37% for patients treated prior to 1975. In the 1980s, the US collaborative Children’s Cancer Group studied a regimen consisting of cyclophosphamide, vincristine, MTX (at a dose of 300 mg/m², higher than that typically used in SSA but logarithmically lower than contemporary HIC dosing), and prednisone, with or without daunorubicin. The addition of an anthracycline in this trial did not influence 10-year EFS, which remained modest at 55% (without daunorubicin) vs 57% (with daunorubicin). In stark contrast to SSA, treatment protocols for BL in the United States and Europe iteratively evolved through the 1980s and 1990s to intensive multiagent regimens with a risk-adapted approach, achieving long-term survival rates that now surpass 90%. The 2 most widely used protocols for pediatric BL worldwide are derived from the French-American-British (FAB)/Lymphomes Malins B (LMB) collaboration and the Berlin-Frankfurt-Münster (BFM) consortium; both groups use similar risk-stratification systems, with stage III/IV disease and elevated lactate dehydrogenase (LDH) levels serving as determinants of the need to intensify
Table 1. Survival patterns for pediatric BL treated with various chemotherapy regimens in SSA over 5 decades

| Location          | Years          | Sample size, n | Regimen           | Chemotherapy dose, mg/m² per cycle | Survival analysis | Stage III/IV survival, % | TRM, % | Cohort survival, % |
|-------------------|----------------|----------------|-------------------|-------------------------------------|-------------------|--------------------------|--------|---------------------|
| Uganda            | 1967-1970      | 57             | Cyclophos         | 1200 — — — — OS                    | 24/0              | 18                       | 30     |
| Ghana             | 1968-1972      | 110            | Cyclophos         | 1200 — — — — 2 y OS                | 31/20             | NR                       | 44     |
| Uganda            | 1967-1977      | 280            | Various*          | OS                                  | 50/25             | NR                       | 39     |
| Ghana             | 2000-2002      | 42             | Plus hdMTX       | 500 2000 2 — 420 1 y EFS           | 24/25             | 33                       | 33     |
| GFAOP 3           | 2001-2004      | 187            | COPM              | 1500 3000 1.5 — 300 1 y EFS        | 52/36             | 21                       | 56     |
| GFAOP 6           | 2005-2008      | 178            | Cyclophos         | 1200 — — — 1 y EFS                | 30/16             | 8                        | 33     |
| Cameroon          | 2006-2008      | 95             | Cyclophos         | 1200-1800 — — — 1 y EFS           | 33                | 7                        | 35     |
| Kenya             | 2008-2011      | 428            | Plus doxo        | 1200 — 1.5 60 Tapering 1 y EFS    | NR                | NR                       | 31     |
| Blantyre, Malawi  | 2010-2012      | 70             | Plus VCR         | 1200-1800 — 1.5 — — 1 y EFS       | 24/32             | 3                        | 48     |
| Lilongwe, Malawi  | 2011-2013      | 74             | CHOP-like         | 800 — 1.5 40 300 18 mo OS         | 26                | 8                        | 29     |
| GFAOP 7           | 2009-2015      | 400            | COPM              | 1500 3000 1.5 — 420 1 y OS        | 60/31             | 12                       | 60     |
| Lilongwe, Malawi  | 2013-2015      | 73             | CHOP-like         | 800 — 1.5 40 300 18 mo OS         | 28/17             | 16                       | 29     |
| Uganda            | 2012-2017      | 180            | COM               | 900 15 1.5 — — 4 y OS             | 42                | NR                       | 44     |

Groupe Franco-Africain d’Oncologie Pédiatrique (GFAOP) 3 includes Cameroon, Madagascar, and Senegal; GFAOP 6 includes Cameroon, Madagascar, Senegal, Burkina-Faso, Ivory Coast, and Mali; and GFAOP 7 includes GFAOP 6 + Togo.

—, not applicable; CHOP-like, cyclophosphamide, doxorubicin, vincristine, and prednisone; COPM, cyclophosphamide, vincristine, prednisone, and hdMTX for 2 cycles, followed by hdMTX plus mini-cytarabine (500 mg/m² per cycle) for 2 cycles; cyclophosphamide, cyclophosphamide monotherapy; Doxo, doxorubicin; EFS, event-free survival; hdMTX, high-dose MTX; NR, not reported; Pred, prednisone; TRM, treatment-related mortality; VCR, vincristine.

*The various regimens used in Uganda from 1967 to 1977 included cyclophosphamide monotherapy (1200 mg/m² per cycle), COM (cyclophosphamide 900 mg/m² per cycle, vincristine 2 mg/m² per cycle, and MTX 45 mg/m² per cycle), and cyclophosphamide 1200 mg/m² per cycle, vincristine 1.4 mg/m² per cycle, MTX 60 mg/m² per cycle, and cytarabine, 750 mg/m² per cycle.
therapy (Table 2). In both constructs, the lowest-risk groups of patients (group A and group R1) are those with completely resected stage I or II tumors. This subgroup of patients is very rare in SSA. Therefore, the vast majority of patients with endemic BL are categorized as being in the analogous intermediate-risk R2/R3 and group B subcategories, as well as in the highest-risk R4/group C subsets.

In the 1980s and 1990s, the French LMB and German BFM collaborative groups, along with St. Jude Children’s Research Hospital, pioneered the use of short intensive combination chemotherapy protocols, including alkylating agents, high-dose MTX (hdMTX; for intermediate and high-risk patients), and high-dose cytarabine (for high-risk patients), to achieve long-term survival in the majority of children with BL. This approach has optimized the systemic and CNS benefits of hdMTX and cytarabine and established the importance of intensity (ie, fewer shorter higher-dose chemotherapy cycles) compared with the prolonged, but lower-intensity, treatment regimens of the past. This approach has optimized the systemic and CNS benefits of hdMTX and cytarabine and established the importance of intensity (ie, fewer shorter higher-dose chemotherapy cycles) compared with the prolonged, but lower-intensity, treatment regimens of the past.61,70,71

The strongest evidence for the indispensable role of hdMTX in improving curative outcomes in children with advanced-stage BL stems from the work of Reiter et al in their 1999 publication comparing the BFM86 and BFM90 protocols.62 The 2 regimens were essentially identical with the exception of 1 major adjustment: an increase in MTX dose from 500 mg/m² (BFM86) to 5000 mg/m² (BFM90).62,72 The impact of this MTX dose intensification, which at the time was administered as a 24-hour infusion for all patients, was greatest in patients with abdominal stage III disease and LDH ≥500 U/L. The 6-year EFS for this subset of patients with advanced-stage disease increased from 43% in BFM86 to 81% in BFM90.62 These data highlight the critical importance of hdMTX in curative therapy for pediatric BL. Although there are slight differences between the LMB and BFM regimens, they have a similar structure. The chemotherapy agents consist of hdMTX, alkylating agents (cyclophosphamide only in LMB, and alternating cyclophosphamide/ifosfamide in BFM), doxorubicin, vincristine, cytarabine, etoposide, and glucocorticoids (Tables 3 and 4). Recent reviews of the treatment of pediatric
The use of high-intensity chemotherapy and immune-depleting agents comes with significant risk for end-organ damage and TRM. High-dose cytarabine and the combination of doxorubicin with MTX are associated with significant infectious morbidity. High doses of MTX are also associated with risk for acute kidney injury and severe mucositis. Pediatric cancer treatment programs in HICs have successfully mitigated the severity and occurrence of these adverse events with comprehensive supportive care measures and routine use of supportive pharmacological agents, such as folic acid, hyperhydration with bicarbonate-based IV fluids, granulocyte colony-stimulating factor, empiric broad-spectrum antibacterial treatment in the setting of febrile illnesses, and blood product support. More recently, even for the highest-risk patients, the addition of rituximab (an anti-CD20 monoclonal antibody) to the standard chemotherapy backbones has propelled curative outcomes beyond 90%.13,14,16,73

Other important nuances in the difference between the BFM and LMB regimens arise in the duration of infusion time of hdMTX (Table 2). The early BFM regimens uniformly administered hdMTX over 24 hours.62,72 The BFM95 study compared 4- vs 24-hour MTX infusions and demonstrated that regimens with 4-hour infusions were significantly less toxic, with a lower incidence of grade III/IV mucositis. However, although treatment with 4-hour infusions was not inferior to 24-hour infusions for patients with lower-risk R1 and R2 disease, the probability of failure-free survival at 1 year was inferior for risk groups R3 and R4 (77% for those receiving 4-hour infusions compared with 93% for those receiving 24-hour infusions; \( P = .0077 \)).63 Based on these data, BFM regimens stratify the intensity of MTX dosing based on risk group, adjusting the dose and infusion time (Table 2). The LMB regimen also adjusts the infusion time of hdMTX, reserving the 24-hour infusion duration for CNS patients who had blasts identified in the CSF. Otherwise, intermediate-risk group B patients receive MTX over a 3-hour duration and CSF group C patients receive it over 4 hours, with the most recent international clinical trial demonstrating a 3-year EFS of 93.9% with rituximab plus LMB backbone chemotherapy for the high-risk group B and group C patients (Table 2).16 Thus, although the BFM95 data demonstrated superior outcomes for advanced-stage patients receiving the more intense 24-hour MTX infusions, the favorable outcomes for CSF patients receiving shorter infusions in the LMB experience suggest that 24-hour infusions may be reserved for CSF patients only. One must also consider the increased toxicity associated with longer-duration MTX infusions, particularly in settings with limited resources for supportive care, where severe mucositis and/or acute kidney injury may have drastic consequences.

The use of current LMB- or BFM-based treatment regimens is limited to tertiary-level pediatric centers that have infrastructure for essential pathology services, diagnostic imaging and laboratory infrastructure for accurate risk stratification, and advanced capacity for supportive care, including intensive care units, blood banking services, and adequate nutritional support. As a result, these advances have mostly benefitted children in HICs and have not been adopted in low- and middle-income countries (LMICs), including SSA, where the vast majority of children with BL live, underlining the wide disparity in survival of children with BL.

### Advancing treatment of BL in SSA

#### Improving diagnosis and risk stratification of endemic BL

Establishing an accurate diagnosis is a critical first step to improving the survival of children with BL in SSA (Figure 2). The most common limitation in the diagnostic accuracy of BL in LMICs is the reliance on clinical diagnosis in children with jaw tumors and morphology alone when tumor tissue is obtained, typically by fine needle aspiration.17 Our experience in SSA is that abdominal tumors are as common as jaw tumors as a presenting feature of BL in children, creating a diagnostic conundrum in differentiating between other abdominal lymphoma diagnoses, as well as the common solid tumors of the abdomen (ie, Wilms tumor, neuroblastoma, and germ cell tumors).17 To further complicate matters, rhabdomyosarcoma and lymphoblastic lymphoma may also present as jaw masses. Advanced orbital retinoblastoma can be indistinguishable from a maxillary or periorbital BL mass. Furthermore, the morphologic appearance of small round blue cells is not unique to BL; it is typical of other common pediatric malignancies, including lymphoblastic lymphoma, rhabdomyosarcoma, Wilms tumor, Ewing sarcoma, retinoblastoma, and neuroblastoma, among others. Even nonmalignant lymphadenopathy has been mistakenly diagnosed as BL.17-19 Alas, treatment outcomes are only as reliable as the diagnostic accuracy of the cohort of patients. Although cytoplasmic vacuolations, tinged body macrophages, and starry sky appearance are all morphological features considered unique to BL, they can be absent, and their diagnostic specificity is unknown; however, studies of diagnostic accuracy of morphology alone suggest that the specificity is ~50% at best.18,19

Establishment of laboratory infrastructure to ensure access to the World Health Organization minimum criteria, including immunophenotyping by immunohistochemistry or multiparametric flow...
cytometry for diagnosis of BL, is feasible in most countries in SSA. Flow cytometry is particularly advantageous because it can use tumor samples obtained by fine needle aspiration and precludes the need for general anesthesia, enables concurrent diagnoses of other hematological malignancies, is timelier than immunohistochemistry, and can be built on existing HIV immunology research infrastructure that is now widely available in many countries in SSA.17,22,23,74-79

The current standard for treating pediatric BL in HICs requires accurate diagnosis to distinguish NHL arising from germinal center B cells (ie, BL and DLBCL), which are treated the same, vs other NHLs, such as those arising from T cells or precursor B cells, which require a different therapeutic strategy. In addition to morphological features consistent with lymphoid malignant proliferation, accurate diagnosis of BL requires immunophenotyping to demonstrate B-cell lineage of the malignant cells (eg, CD20, CD10) and to demonstrate the maturity of the malignant clone (eg, terminal deoxynucleotidyl transferase–negative and κ or λ surface immunoglobulin restriction). Although pediatric BL and DLBCL are treated the same in current standardized protocols, the 2 can sometimes be distinguished by a very high proliferative index in the case of BL, using Ki67, and demonstration of translocations involving C-MYC and any of the 3 immunoglobulin genes (IGH, IGK, or IGL). Risk-adapted treatment requires accurate risk stratification to tailor chemotherapy intensity to risk of relapse. Comprehensive staging evaluation requires light microscopy of a CSF cytospin sample and bone marrow aspirate or biopsy, in addition to computed tomography diagnostic imaging. The standard risk-stratification platform incorporates the pediatric NHL St. Jude Research Hospital’s staging classification and baseline LDH level.8,11,15,63

Escalating MTX dosing tailored to available supportive care in SSA

Current best evidence is that high-intensity cytotoxic chemotherapy is critical to cure BL, particularly in children with intermediate- and high-risk disease. Based on experiences with the LMB and BFM regimens discussed above, MTX is a critical agent in the cure of BL. Given the inability of pediatric centers in SSA to provide the level of supportive care necessary to safely implement the full complement of current gold standard LMB- and BFM-based regimens, graduated and step-wise escalation of MTX doses should be tailored

Table 3. Schematic comparison of the FAB/LMB and BFM risk-stratified chemotherapy regimens

| Risk strata | Regimen | Prephase | Chemotherapy phases |
|-------------|---------|----------|---------------------|
| Low risk    | FAB/LMB group A | None | COPAD COPAD |
| Intermediate risk | BFM R2 | V | COP COPADM COPADM CYM CYM |
|              | BFM R3 | V | AA BB CC AA BB |
| High risk   | FAB/LMB group C | COP | COPADM COPADM2 CYVE CYVE m1 m2 |
|             | BFM R4 | V | AA BB CC AA BB |

A, cycle A; AA, cycle AA; B, cycle B; BB, cycle BB; CC, cycle CC; COP, COP pre-phase; COPADM, induction phase; COPADM2, induction phase; CYM, consolidation phase; CYVE, consolidation phase; m1, maintenance phase 1; m2, maintenance 2; V, pre-phase.

Table 4. Comparison of chemotherapy combinations and doses in the FAB/LMB and BFM regimens

| Regimen | Phase of therapy | Chemotherapeutic agents and doses per phase, mg/m² | IT doses, n |
|---------|------------------|--------------------------------------------------|-------------|
| BFM     | V                | 400— — D: 40 — — — — — — 1 | |
| A       | — 1.5* — D: 50 — — 1000 600 200 4000 1 | |
| B       | 1000— 1.5* — D: 50 50 1000 — — — — — 1 | |
| AA      | — 1.5 — D: 50 — — 5000 600 200 4000 2† | |
| BB      | 1000— 1.5 — D: 50 50 5000 — — — — — 2† | |
| CC      | — 3* — D: 100 — — 12000 500 — — 1† | |
| LMB     | COP              | 300 1 — P: 420 — — — — — — 1† | |
| COPAD   | 1500 4 — P: 360 60 — — — — — — 0 | |
| COPADM  | 1500 2 — P: 300 60 3000-8000# — — — — 2† | |
| COPADM2 | 3000 2 — P: 300 60 8000 — — — — 3 | |
| CYM     | — — — — — — 3000 500 — — — 2 | |
| CYVE    | — — — — — — 8000† 12250 800 — 1-2‡ | |
| m1      | 1000 2 — P: 300 60 8000 — — — — — 1 | |
| m2      | — — — — — — 500 450 — — 0 | |

Cycl, cyclophosphamide; Cyta, cytarabine; D, dexamethasone; Etop, etoposide; Ifos, ifosfamide; IT, intrathecal; P, prednisone.

*Vincristine is omitted from the BFM R1 regimen and is replaced by vindesine in the CC phase of therapy.
†Additional IT therapy is administered to patients with CNS involvement in the BFM regimen, as well as for patients in LMB group C.
‡Dose of MTX is 3000 mg/m² for patients in group B and 8000 mg/m² for patients in group C in LMB.
§High-dose MTX and an additional dose of intrathecal chemotherapy is given to patients with CNS involvement during 1st CYVE phase only.
to the available supportive care infrastructure. Although concerted efforts continue to focus on improving the clinical infrastructure in centers in SSA, this should not negate attempts to advance beyond low-dose MTX and low-intensity cyclophosphamide regimens that have stalled progress in improving survival of African children with BL in the past 50 years.

In Blantyre, Malawi, a regimen using 2000 mg/m² MTX (infused over 3 hours), in combination with cyclophosphamide and vincristine, resulted in a disappointing 1-year EFS of 33%, with a high TRM of 33%; any potential gains made by intensification of MTX were probably lost in TRM.80 Notably, this regimen used a dose of cyclophosphamide (500 mg/m²) that is lower than typically used, even in SSA regimens. Around the same time period, from 2001 to 2004, the Groupe Franco-Africain d’Oncologie Pédiatrique (GFAOP) collaboration in Cameroon, Madagascar, and Senegal escalated pediatric BL treatment from cyclophosphamide monotherapy (1-year EFS = 33%) to cyclophosphamide, vincristine, MTX, and prednisone, using an MTX dose of 3000 mg/m² (infused over 3 hours).41 This higher-intensity regimen was initially characterized by high TRM rates (26% in the first year) at GFAOP centers; however, with ongoing improvements in supportive care, TRM decreased with each year of the study (second year TRM = 19%, third year TRM = 12%).81 The authors attributed these improvements to enhanced prevention and treatment of infections and tumor lysis syndrome.81

More recently, the GFAOP published a larger (n = 400) multicenter experience involving 7 sites in SSA. They were able to reproduce the superior outcomes seen in the earlier experience with a 1-year OS of 60% for patients with advanced-stage disease and a TRM of 12%.51 Using a modified LMB regimen, they continued to deliver the first 2 induction cycles with cyclophosphamide, vincristine, prednisone, and hdMTX for 2 cycles, followed by hdMTX plus mini-cytarabine (500 mg/m² per cycle) for 2 cycles, including 3000 mg/m² of MTX over 3 hours.51 The progress made by GFAOP highlights the necessity for enhanced supportive care along with intensified MTX.

How much MTX is enough?

Doses and infusion duration of MTX used in the treatment of pediatric BL in the United States and Europe have varied over time and depend on risk stratification (Table 2). The BFM86 protocol, which administered 500 mg/m² of MTX over 24 hours, reported a 6-year EFS of 99% for patients with stage I/II disease.62,72 In BFM95, patients in low-intermediate–risk groups R1 and R2 received 1000 mg/m² over 4 hours and achieved a similar 3-year EFS of 98%; this dose has been used for R1 and R2 strata in the BFM regimen ever since.63 For higher-risk R3 and R4 patients, higher doses of MTX with longer infusion times were considered necessary. As previously mentioned, the BFM90 regimen used 5000 mg/m² of MTX over 24 hours to achieve improved long-term EFS in patients with advanced-stage disease (Table 5).62

In the current BFM regimen NCT03206671, patients in low-intermediate–risk groups R1 and R2 receive 1000 mg/m² of MTX infused over 4 hours, whereas the intermediate-high–risk groups R3 and R4 receive 5000 mg/m² infused over 24 hours.62,63,72 In the LMB regimens, intermediate-risk patients (group B) receive 3000 mg/m² over 3 hours, whereas high-risk patients (group C) receive 8000 mg/m² over 3 hours (CSF¹) or over 24 hours (CSF²) (Table 2). An important caveat is that the LMB regimen incorporates 2 cycles containing high-dose cytarabine for group C patients, whereas the BFM regimen includes 1 cycle of high-dose cytarabine for risk group R3 and 2 cycles for risk group R4. The use of high-dose cytarabine is associated with a high risk for infectious morbidity and mortality due to prolonged severe neutropenia.11 Therefore, this
subset of high-risk patients may present the greatest challenge to improving curative outcomes in low-income settings in SSA. Nonetheless, other pediatric oncology centers in LMICs around the world have established precedent for improving curative outcomes for children with BL by delivering risk-stratified treatment based on adapted regimens, with or without dose modifications of hdMTX.

Table 4 summarizes the nuances of intermediate-high-dose MTX (starting from 500 mg/m²) that have been used in pediatric BL.62,63,72,81-87 Multiple cohorts from Central and South America had long-term EFS rates ranging from 55% to 82% for patients with stage III BL utilizing regimens with intermediate-dose MTX (1000-2000 mg/m²), typically infused over 3 hours; the only exception was the study in Argentina, which was based on the BFM90 approach with 24-hour infusions.82-84,87 Although considerations to reduce MTX doses in HICs are counteracted by the dismal survival of children with relapsed BL, only lower doses of MTX are safely feasible in most SSA centers. It will be critical to determine the safest most effective dosing range and infusion duration to optimize curative outcomes in a risk-stratified manner for children with BL in low-income settings.

Potential impact of rituximab in the treatment of BL in SSA

The anti-CD20 monoclonal antibody rituximab has been incorporated into the treatment of pediatric BL for nearly 2 decades. It was initially used with combination chemotherapy in the setting of relapsed and refractory disease and has since been evaluated as upfront therapy for children with BL in Africa.42,94-100 The feasibility of giving rituximab to adults with lymphoma in Africa has already been established, and its incorporation in the treatment of pediatric mature B-cell NHL in Eastern Europe has demonstrated efficacy and tolerability.111,112 The addition of rituximab to chemotherapy regimens for children with BL in Africa will enable the establishment of safer, less-intense multiagent chemotherapy regimens that can optimize treatment response while mitigating the severe consequences of treatment failure.

Optimization of MTX dose and infusion duration at treatment centers in SSA will vary based on locally available resources. The feasibility of giving rituximab for children with BL and DLBCL living in LMICs has already been established, and its incorporation in the treatment of pediatric mature B-cell NHL in Eastern Europe has demonstrated efficacy and tolerability.111,112 The addition of rituximab to chemotherapy regimens for children with BL in Africa will enable the establishment of safer, less-intense multiagent chemotherapy regimens that can optimize treatment response while mitigating the severe consequences of treatment failure.

Next steps in optimizing hdMTX in SSA

Optimization of MTX dose and infusion duration at treatment centers in SSA will vary based on locally available resources. The feasibility of giving rituximab for children with BL and DLBCL living in LMICs has already been established, and its incorporation in the treatment of pediatric mature B-cell NHL in Eastern Europe has demonstrated efficacy and tolerability.111,112 The addition of rituximab to chemotherapy regimens for children with BL in Africa will enable the establishment of safer, less-intense multiagent chemotherapy regimens that can optimize treatment response while mitigating the severe consequences of treatment failure. The anti-CD20 monoclonal antibody rituximab has been incorporated into the treatment of pediatric BL for nearly 2 decades. It was initially used with combination chemotherapy in the setting of relapsed and refractory disease and has since been evaluated as upfront therapy for children with BL in Africa.42,94-100 The feasibility of giving rituximab to adults with lymphoma in Africa has already been established, and its incorporation in the treatment of pediatric mature B-cell NHL in Eastern Europe has demonstrated efficacy and tolerability.111,112 The addition of rituximab to chemotherapy regimens for children with BL in Africa will enable the establishment of safer, less-intense multiagent chemotherapy regimens that can optimize treatment response while mitigating the severe consequences of treatment failure.

Table 5. Outcomes for childhood and adolescent mature B-cell NHL with historical treatment regimens from Europe plus middle-income countries

| Location          | Years       | Sample size, n | Regimen basis | MTX dose utilized, mg/m² | Survival analysis | Cohort survival, % | TRM, % | Survival by stage/risk group |
|-------------------|-------------|----------------|---------------|--------------------------|------------------|--------------------|--------|------------------------------|
| BRM               | 1986-1990  | 197            | BFM86        | 500                      | 6-y EFS          | 82                 | 5      | Stages I/II 99%; stages III LDH < 500 U/L, 85%; stages III LDH > 500 U/L, 43%; stage IV, 67% |
| BRM               | 1990-1995  | 413            | BFM90        | 5000                     | 6-y EFS          | 89                 | 3      | Stages I/II 98%; stages III LDH < 500 U/L, 95%; stages III LDH > 500 U/L, 81%; stage IV, 73% |
| Brazil            | 1996-2001  | 281            | BFM95*       | 1000                     | 3-y EFS          | 94                 | 0.4    | Group R1, 94%; group R2, 94% |
| Argentina         | 1994-1999  | 57             | BFM90        | 2000                     | ~3-y EFS         | 78                 | 2      | Stages I/II 100%; stages III/IV, 74% |
| Nicaragua         | 1996-2003  | 53             | Unspecified  | 1000                     | 9-y EFS          | 79                 | 9      | Group R1, 100%; group R2, 86%; group R3, 82%; group R4, 50% |
| Brazil            | 1995-2002  | 96             | LMB89        | Unmodified               | 3-y EFS          | 75                 | 9      | Group A, 100%; group B, 76%; group C, 56% |
| South Africa      | 1995-2010  | 51             | LMB89        | Unmodified               | 5-y OS           | 65                 | NR     | Stage II, 62%; stage III, 78%; stage IV, 42% |
| Northwest Africa  | 2001-2004  | 53             | LMB89        | Unmodified               | 3-y OS           | 75                 | 21     | Stages I/II, 84%; stage III, 76%; stage IV, 56% |
| Central America   | 2004-2016  | 405            | BRM90        | 1000-3000                | 3-y EFS          | 70                 | 11     | Stages I/II, 83%; stage III, 75%; stage IV, 56% |

*BFM95 data focus on regimen for risk groups R1 and R2 only, excluding risk groups R3 and R4, which received a higher dose of MTX.
including the multidisciplinary support required to safely and effectively administer the drug. Practical issues, such as night-staff availability and access to resources required for hyperhydration and leucovorin rescue, are critically important. One consideration is to escalate MTX dosing in a stepwise fashion, starting with a modest dose, such as 1000 mg/m² infused over 3 hours. This dose has demonstrated efficacy for patients categorized as R2 in the BFM regimen and would at least include those with stage I/II disease, as well as stage III with low LDH. As centers establish safety with this initial dose, stepwise escalation up to 3000 mg/m² infused over 3 hours will be a reasonable goal. This dose has proven efficacy for high-risk group B patients in the LMB regimen, including those with stage III disease and elevated LDH, extending curative potential to the majority of patients with BL. Escalation beyond these doses, and to longer infusions of MTX, may be goals reserved for future time points when treatment centers have greater infrastructure to deliver such intensive regimens.

Conclusions

Pediatric BL is emblematic of the disparities in survival of children with cancer worldwide. Advances in pediatric oncology in the United States and Europe blossomed through the development of clinical trial networks. In Africa, collaborative programs turned the tides of the HIV/AIDS epidemic. Collaborative clinical trial networks like the GFAOP are now required to systematically catalyze outcomes for children with cancer in SSA. Multidisciplinary specialized services, including nursing, pharmacy, nutrition, diagnostic pathology, blood banking, radiology, palliative care, pediatric surgery, and critical care, are key to improving pediatric cancer survival. Rational and feasible interim measures to improve outcomes of children with cancer in these settings should focus on adapting current best evidence to the resources, infrastructure, and putative unique biology of some of the cancers in children in LMICs. In the case of BL, the GFAOP approach of escalating MTX with concomitant supportive care through multicenter clinical trials performed through a cooperative group structure has improved outcomes. Careful implementation of higher MTX doses with combination chemotherapy in the setting of systematic supportive care infrastructure building is prudent. This stepwise escalation with ongoing rigorous evaluation and measurement of TRM may also offer the opportunity to establish the correct balance of intensity of cytotoxic chemotherapy for BL in the context of wider accessibility to anti-CD20 humoral immunotherapy globally.

Authorship

Contribution: N.W.O., J.L., and N.K.E.-M. designed the research, analyzed the data, and wrote the manuscript; and C.E.A. analyzed the data and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial conflicts.

ORCID profile: N.K.E.-M., 0000-0001-6115-1046.

Correspondence: Nader Kim El-Mallawany, Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE, Lymphoma and Histiocytosis Team, 1102 Bates St Feigin Tower, Room 1025.16, Houston, TX 77030; e-mail: nader.el-mallawany@bcm.edu.

References

1. Atun R, Bhakta N, Denburg A, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol. 2020;21(4):e185-e224.
2. Burkitt D, Hutt MS, Wright DH. The African lymphoma: preliminary observations on response to therapy. Cancer. 1965;18(4):399-410.
3. Allen CE, Kelly KM, Bollard CM. Pediatric lymphomas and histiocytic disorders of childhood. Pediatr Clin North Am. 2015;62(1):139-165.
4. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1(7335):702-703.
5. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 1978;79(24):7824-7827.
6. Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science. 1983;219(4587):963-967.
7. Dave SS, Fu K, Wright GW, et al; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2008; 354(23):2431-2442.
8. Epstein A. Burkitt lymphoma and the discovery of Epstein-Barr virus. Br J Haematol. 2012;156(6):777-779.
9. Gerrard M, Cairo MS, Weston C, et al; FAB LMB96 International Study Committee. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008; 141(6):840-847.
10. Patte C, Auperin A, Gerrard M, et al; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773-2780.
11. Cairo MS, Gerrard M, Sposto R, et al; FAB LMB96 International Study Committee. Results of a randomized international study of high-risk central nervous system B non-Hodgkin’s lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2738-2743.
12. Burkhardt B, Oschlies I, Klapper W, et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. 2011;25(1):153-160.
13. Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukemia: a Children’s Oncology Group Report. Br J Haematol. 2014;167(3):394-401.
Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia. 2013;27(5):1174-1177.

Cairo MS, Spoto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387-393.

Minard-Colin V, Aupérin A, Pillon M, et al; Children’s Oncology Group. Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children. N Engl J Med. 2020;382(23):2207-2219.

El-Mallahawy NK, Mutai M, Mtefe I, et al. Beyond endemic Burkitt lymphoma: navigating challenges of differentiating childhood lymphoma diagnoses amid limited resources in Lilongwe, Malawi. Glob Pediatr Health. 2017;4:2337974X17715831.

Ogwang MD, Zhao W, Ayers LW, Mbulaiteye SM. Accuracy of Burkitt lymphoma diagnosis in constrained pathology settings: importance to epidemiology. Arch Pathol Lab Med. 2011;135(4):445-450.

Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood. 2018;132(3):254-263.

Carey P, Fudzulani R, Scholfield D, et al. Remote and rapid pathological diagnosis in a resource-challenged unit. J Clin Pathol. 2014;67(6):540-543.

Gopal S, Krysiak R, Liomba NG, et al. Early experience after developing a pathology laboratory in Malawi, with emphasis on cancer diagnoses. PLoS One. 2013;8(8):e70361.

Gopal S, Krysiak R, Liomba G. Building a pathology laboratory in Malawi. Lancet Oncol. 2013;14(4):291-292.

Lubega J, Airewele G, Frugé E, et al. Capacity building: a novel pediatric hematology-oncology fellowship program in sub-Saharan Africa. J Clin Oncol. 2018;36(34):e2017-e2018.

Ziegler JL, Katongole-Mbidde E, Otim D, Lnonga SK, Magrath IT, Ziegler JL. Long-term experience with Burkitt’s lymphoma in Uganda. Int J Cancer. 1980;26(3):261-266.

Ziegler JL, Morrow RH Jr., Fass L, Kyalwazi SK, Carbone PP. Treatment of Burkitt’s tumor with cyclophosphamide. Cancer. 1970;26(2):474-484.

Olweny CL, Katongole-Mbidde E, Kaddu-Mukasa A, et al. Treatment of Burkitt’s lymphoma: randomized clinical trial of single-agent versus combination chemotherapy. Int J Cancer. 1976;17(4):436-440.

Magrath I, Lee YJ, Anderson T, et al. Prognostic factors in Burkitt’s lymphoma: importance of total tumor burden. Cancer. 1980;45(6):1507-1515.

Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 1992;6(3):163-173.

Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997;17(5 Pt 2):148S-154S.

Ziegler JL, Bluming AZ. Intrathecal chemotherapy in Burkitt’s lymphoma. BMJ. 1971;3(5773):508-512.

Olweny CL, Atine I, Kaddu-Mukasa A, et al. Cerebrospinal irradiation of Burkitt’s lymphoma. Failure in preventing central nervous system relapse. Acta Radiol Ther Phys Biol. 1977;16(3):225-231.

Ziegler JL, Bluming AZ, Magrath IT, Carbone PP. Intensive chemotherapy in patients with generalized Burkitt’s lymphoma. Int J Cancer. 1972;10(2):254-261.

Nkrumah FK, Perkins IV, Biggar RJ. Combination chemotherapy in abdominal Burkitt’s lymphoma. Cancer. 1977;40(4):1410-1416.

Kazembe P, Hesseling PB, Griffin BE, Lampert I, Wessels G. Long term survival of children with Burkitt lymphoma in Malawi after cyclophosphamide monotherapy. Med Pediatr Oncol. 2003;40(1):23-25.

Hesseling P, Isaacs T, Harif M, Chantada G, Molynex E; Pediatric Oncology in Developing Countries. Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting. Pediatr Blood Cancer. 2013;60(3):357-362.

Hesseling PB, Molynex E, Chintesme F, et al. Treating Burkitt’s lymphoma in Malawi, Cameroon, and Ghana. Lancet Oncol. 2008;9(6):512-513.

Traore F, Coze C, Atteby JJ, et al. Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2011;56(1):70-76.

Orem J, Mulumba Y, Algeri S, et al. Clinical characteristics, treatment and outcome of childhood Burkitt’s lymphoma at the Uganda Cancer Institute. Trans R Soc Trop Med Hyg. 2011;105(12):717-726.

Ngoma T, Adde M, Durowsi M, et al. Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease. Br J Haematol. 2012;158(6):749-762.

McGoldrick SM, Mutyaba I, Adams SV, et al. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda. Pediatr Blood Cancer. 2019;66(9):e27813.
45. Depani S, Banda K, Bailey S, Israelis T, Chagaluka G, Molyneux E. Outcome is unchanged by adding vincristine upfront to the Malawi 28-day protocol for endemic Burkitt lymphoma. *Pediatr Blood Cancer*. 2015;62(11):1929-1934.

46. Stanley CC, Westmoreland KD, Heimlich BJ, et al. Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. *Br J Haematol*. 2016;173(5):705-712.

47. Buckle G, Maranda L, Skiles J, et al. Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study. *Int J Cancer*. 2016;139(6):1231-1240.

48. Nkrumah FK, Perkins IV. Burkitt’s lymphoma: a clinical study of 110 patients. *Cancer*. 1976;37(2):671-676.

49. Marjerison S, Fernandez CV, Price VE, Njume E, Hesseling P. The use of ultrasound in endemic Burkitt lymphoma in Cameroon. *Pediatr Blood Cancer*. 2012;58(3):352-355.

50. Hesseling PB, Njume E, Kouya F, et al. The Cameroon 2008 Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy. *Pediatr Hematol Oncol*. 2012;29(2):119-129.

51. Bouda GC, Traoré F, Couitchere L, et al. Advanced Burkitt lymphoma in sub-Saharan Africa pediatric units: results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d’Oncologie Pédiatrique. *J Glob Oncol*. 2019;5:1-9.

52. Offor UT, Akyea RK, Neequaye JE, Renner LA, Segbefia CJ. The changing clinical pattern of endemic Burkitt lymphoma in Western Africa: experience from a tertiary center in Ghana. *Pediatr Blood Cancer*. 2018;65(10):e27275.

53. Ziegler JL, Magrath IT, Olweny CL. Cure of Burkitt lymphoma. Ten-year follow-up of 157 Ugandan patients. *Lancet*. 1979;2(8149):936-938.

54. Molyneux E, Schwalbe E, Chagaluka G, et al. The use of anthracyclines in the treatment of endemic Burkitt lymphoma. *Br J Haematol*. 2017;177(6):984-990.

55. Westmoreland KD, El-Mallawany NK, Kazembe P, Stanley CC, Gopal S. Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment. *Br J Haematol*. 2018;181(6):853-854.

56. Murphy SB, Hustin HO. A randomized trial of combined modality therapy of childhood non-Hodgkin’s lymphoma. *Cancer*. 1980;45(4):630-637.

57. Magrath I. Towards curative therapy in Burkitt lymphoma: the role of early African studies in demonstrating the value of combination therapy and CNS prophylaxis. *Adv Hematol*. 2012;2012:130680.

58. Murphy SB, Fairclough DL, Hutchinson RE, Berard CW. Non-Hodgkin’s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. *J Clin Oncol*. 1989;7(2):186-193.

59. Cairo MS, Spoto R, Perkins SL, et al. Burkitt’s and Burkitt-like lymphoma in children and adolescents: a review of the Children’s Cancer Group experience. *Br J Haematol*. 2003;120(4):660-670.

60. Spoto R, Meadows AT, Chilcote RR, et al. Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: a report from the Children’s Cancer Group. *Med Pediatr Oncol*. 2001;37(5):432-441.

61. El-Mallawany NK, Cairo MS. Advances in diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. *Clin Adv Hematol Oncol*. 2015;13(2):113-123.

62. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. *Blood*. 1999;94(10):3294-3306.

63. Woessmann W, Seidemann K, Mann G, et al; BFM Group. The impact of the methotrexate administration schedule and dose in the treatment of children with acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. *J Clin Oncol*. 1986;4(12):1732-1739.

64. Meinhardt A, Burkhardt B, Zimmermann M, et al; Berlin-Frankfurt-Münster group. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. *J Clin Oncol*. 2010;28(19):3115-3121.

65. Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. *J Clin Oncol*. 1991;9(1):123-132.

66. Patte C, Auperin A, Michon J, et al; Société Française d’Oncologie Pédiatrique. The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. *Blood*. 2001;97(11):3370-3379.

67. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt’s lymphoma and B cell (Slg +) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. *J Clin Oncol*. 1986;4(12):1732-1739.

68. Bollard CM, Lim MS, Gross TG; COG Non-Hodgkin Lymphoma Committee. Children’s Oncology Group’s 2013 blueprint for research: non-Hodgkin lymphoma. *Pediatr Blood Cancer*. 2013;60(6):979-984.

69. Minard-Colin V, Brugière L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. *J Clin Oncol*. 2015;33(27):2963-2974.

70. Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. *Br J Haematol*. 2008;142(3):329-347.

71. Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. *Br J Haematol*. 2012;156(6):730-743.

72. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage—a report of the Berlin-Frankfurt-Münster Group. *J Clin Oncol*. 1995;13(2):359-372.
73. Egan G, Goldman S, Alexander S. Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies. Br J Haematol. 2019;185(6):1071-1085.

74. Savage EC, Vanderheyden AD, Bell AM, Syrbu SI, Jensen CS. Independent diagnostic accuracy of flow cytometry obtained from fine-needle aspirates: a 10-year experience with 451 cases. Am J Clin Pathol. 2011;135(2):304-309.

75. Swart GJ, Wright C, Brundyn K, et al. Fine needle aspiration biopsy and flow cytometry in the diagnosis of lymphoma. Transfus Apheresis Sci. 2007;37(1):71-79.

76. Abayomi EA, Landis RC. Flow cytometry as the spearhead for delivering sustainable and versatile laboratory services to HIV-burdened health care systems of the developing world: a Caribbean model. Cytometry B Clin Cytom. 2008;74(suppl 1):S80-S89.

77. Justman JE, Koblavi-Deme S, Tanuri A, Goldberg A, Gonzalez LF, Gwynn CR. Developing laboratory systems and infrastructure for HIV scale-up: A tool for health systems strengthening in resource-limited settings. J Acquir Immune Defic Syndr. 2009;52(suppl 1):S30-S33.

78. Mulry J. Benchtop flow cytometry helps monitor HIV in sub-Saharan Africa. MLO Med Lab Obs. 2012;44(7):32-NaN, 34, 36.

79. Namazzi R, Gaikwad A, Wasswa P, et al. Improving diagnosis and treatment of acute childhood leukemia in Uganda: impact of flow cytometry. Blood Adv. 2018;2(suppl 1):21-23.

80. Hesseling P, Broadhead R, Mansvelt E, et al. The 2000 Burkitt Lymphoma Trial in Malawi. Pediatr Blood Cancer. 2005;44(3):245-250.

81. Harif M, Barsaoui S, Benchekroun S, et al. Treatment of B-cell lymphoma with LMB modified protocols in Africa—report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2008;50(6):1138-1142.

82. Klumb CE, Schramm MT, De Resende LM, et al. Treatment of children with B-cell non-Hodgkin’s lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol. 2004;26(7):462-468.

83. Chantada G, Casak S, Alderete D, Zubizarreta P, Gallo G, Muriel FS. Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in Argentina. Med Pediatr Oncol. 2003;41(5):488-490.

84. Baez F, Pillon M, Manfredini L, et al. Treatment of pediatric non-Hodgkin lymphomas in a country with limited resources: results of the first national protocol in Nicaragua. Pediatr Blood Cancer. 2008;50(1):148-152.

85. Acquatella G, Insauti CL, Garcia R, et al. Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol. Pediatr Blood Cancer. 2004;43(5):580-586.

86. Stefan DC, Lutchman R. Burkitt lymphoma: epidemiological features and survival in a South African centre. Infect Agent Cancer. 2014;9(1):19.

87. Peña-Hernandez A, Ortiz R, Garrido C, et al. Outcome of pediatric non-Hodgkin lymphoma in Central America: a report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA). Pediatr Blood Cancer. 2019;66(5):e27621.

88. Griffin TC, Weitzman S, Weinstein H, et al; Children's Oncology Group. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20 +) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52(2):177-181.

89. Painschab MS, Westmoreland KD, Kasonkanji E, et al. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi. Blood Adv. 2019;3(4):612-620.

90. Maschan A, Myakova N, Aleinkova O, et al. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M. Br J Haematol. 2019;186(3):477-483.

91. Miller H, Slone JS, Raabe E, El-Mallawany NK, Mehta P, Phelps BR. Lessons from pediatric HIV: a case for curative intent in pediatric cancer in LMICs. Pediatrics. 2017;140(4):e20170525.